BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 33266377)

  • 1. Clinical Perspectives of ERCC1 in Bladder Cancer.
    Koutsoukos K; Andrikopoulou A; Dedes N; Zagouri F; Bamias A; Dimopoulos MA
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33266377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression.
    Usanova S; Piée-Staffa A; Sied U; Thomale J; Schneider A; Kaina B; Köberle B
    Mol Cancer; 2010 Sep; 9():248. PubMed ID: 20846399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Excision repair cross-complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy.
    Kim KH; Do IG; Kim HS; Chang MH; Kim HS; Jun HJ; Uhm J; Yi SY; Lim DH; Ji SH; Park MJ; Lee J; Park SH; Kwon GY; Lim HY
    APMIS; 2010 Dec; 118(12):941-8. PubMed ID: 21091775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy.
    Sun JM; Sung JY; Park SH; Kwon GY; Jeong BC; Seo SI; Jeon SS; Lee HM; Jo J; Choi HY; Lim HY
    BMC Cancer; 2012 May; 12():187. PubMed ID: 22616552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy.
    Ozcan MF; Dizdar O; Dincer N; Balcı S; Guler G; Gok B; Pektas G; Seker MM; Aksoy S; Arslan C; Yalcin S; Balbay MD
    Urol Oncol; 2013 Nov; 31(8):1709-15. PubMed ID: 22863869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy.
    Hoffmann AC; Wild P; Leicht C; Bertz S; Danenberg KD; Danenberg PV; Stöhr R; Stöckle M; Lehmann J; Schuler M; Hartmann A
    Neoplasia; 2010 Aug; 12(8):628-36. PubMed ID: 20689757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ERCC1 as a Prognostic and Predictive Biomarker for Urothelial Carcinoma of the Bladder following Radical Cystectomy.
    Klatte T; Seitz C; Rink M; Rouprêt M; Xylinas E; Karakiewicz P; Susani M; Shariat SF
    J Urol; 2015 Nov; 194(5):1456-62. PubMed ID: 26162296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer.
    Friboulet L; Olaussen KA; Pignon JP; Shepherd FA; Tsao MS; Graziano S; Kratzke R; Douillard JY; Seymour L; Pirker R; Filipits M; André F; Solary E; Ponsonnailles F; Robin A; Stoclin A; Dorvault N; Commo F; Adam J; Vanhecke E; Saulnier P; Thomale J; Le Chevalier T; Dunant A; Rousseau V; Le Teuff G; Brambilla E; Soria JC
    N Engl J Med; 2013 Mar; 368(12):1101-10. PubMed ID: 23514287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic significance of human equilibrative nucleoside transporter 1 expression in patients with metastatic bladder cancer treated with gemcitabine-cisplatin-based combination chemotherapy.
    Matsumura N; Nakamura Y; Kohjimoto Y; Inagaki T; Nanpo Y; Yasuoka H; Ohashi Y; Hara I
    BJU Int; 2011 Jul; 108(2 Pt 2):E110-6. PubMed ID: 21166756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ERCC1 expression levels predict the outcome of platinum-based chemotherapies in advanced bladder cancer: a meta-analysis.
    Li S; Wu J; Chen Y; Tang W; Peng Q; Deng Y; Xie L; Wang J; Huang S; Li R; Qin X; Zhao J
    Anticancer Drugs; 2014 Jan; 25(1):106-14. PubMed ID: 24025563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Excision repair cross-complementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer.
    Kawashima A; Nakayama M; Kakuta Y; Abe T; Hatano K; Mukai M; Nagahara A; Nakai Y; Oka D; Takayama H; Yoshioka T; Hoshida Y; Itatani H; Nishimura K; Nonomura N
    Clin Cancer Res; 2011 Apr; 17(8):2561-9. PubMed ID: 21177407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ERCC1 function in nuclear excision and interstrand crosslink repair pathways is mediated exclusively by the ERCC1-202 isoform.
    Friboulet L; Postel-Vinay S; Sourisseau T; Adam J; Stoclin A; Ponsonnailles F; Dorvault N; Commo F; Saulnier P; Salome-Desmoulez S; Pottier G; André F; Kroemer G; Soria JC; Olaussen KA
    Cell Cycle; 2013 Oct; 12(20):3298-306. PubMed ID: 24036546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
    Olaussen KA; Mountzios G; Soria JC
    Curr Opin Pulm Med; 2007 Jul; 13(4):284-9. PubMed ID: 17534174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetics of platinum-based chemotherapy in non-small cell lung cancer: predictive validity of polymorphisms of ERCC1.
    Hamilton G; Rath B
    Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):17-24. PubMed ID: 29226731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of the ERCC1-XPF structure-specific endonuclease to overcome cancer chemoresistance.
    McNeil EM; Astell KR; Ritchie AM; Shave S; Houston DR; Bakrania P; Jones HM; Khurana P; Wallace C; Chapman T; Wear MA; Walkinshaw MD; Saxty B; Melton DW
    DNA Repair (Amst); 2015 Jul; 31():19-28. PubMed ID: 25956741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small Molecule Antagonists of the DNA Repair ERCC1/XPA Protein-Protein Interaction.
    Obermann R; Yemane B; Jarvis C; Franco FM; Kyriukha Y; Nolan W; Gohara B; Krezel AM; Wildman SA; Janetka JW
    ChemMedChem; 2024 Apr; 19(8):e202300648. PubMed ID: 38300970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.
    Bellmunt J; Paz-Ares L; Cuello M; Cecere FL; Albiol S; Guillem V; Gallardo E; Carles J; Mendez P; de la Cruz JJ; Taron M; Rosell R; Baselga J;
    Ann Oncol; 2007 Mar; 18(3):522-8. PubMed ID: 17229776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair.
    Kudo K; Gavin E; Das S; Amable L; Shevde LA; Reed E
    Oncogene; 2012 Nov; 31(44):4718-24. PubMed ID: 22266871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.
    Olaussen KA; Dunant A; Fouret P; Brambilla E; André F; Haddad V; Taranchon E; Filipits M; Pirker R; Popper HH; Stahel R; Sabatier L; Pignon JP; Tursz T; Le Chevalier T; Soria JC;
    N Engl J Med; 2006 Sep; 355(10):983-91. PubMed ID: 16957145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
    Vilmar A; Sørensen JB
    Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.